AIDS Therapies (Saquinavir)

Approval Recommended for First in New Class of Therapies

Published in AIDS Weekly, November 20th, 1995

The Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) recommended approval for Invirase (saquinavir) - the first compound in a new class of AIDS therapies called proteinase (or protease) inhibitors. The last time the FDA recommended approval for a compound from a new class of AIDS therapies was in 1987 (AZT).

Studies show that Invirase can work together with conventional HIV therapies - nucleoside analogues such as AZT (ZDV) and HIVID (ddC) - but has fewer side effects and is well tolerated by patients. Unlike nucleoside analogues, which inhibit the enzyme reverse transcriptase, Invirase blocks the enzyme proteinase. Both enzymes are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-11-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry